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Antiviral potential of 
3′-sialyllactose- and 
6′-sialyllactose-conjugated 
dendritic polymers against human 
and avian influenza viruses
Sira Carolin Günther1, Julian David Maier  1,4, Janine Vetter1,4, Nikita Podvalnyy3, 
Nikolay Khanzhin2, Thierry Hennet3 & Silke Stertz1*
Current treatment options for influenza virus infections in humans are limited and therefore the 
development of novel antivirals is of high priority. Inhibiting influenza virus attachment to host cells 
would provide an early and efficient block of the infection and thus, receptor analogs have been 
considered as options for antiviral treatment. Here, we describe the rapid and efficient synthesis 
of PAMAM dendrimers conjugated with either 3′-sialyllactose (3SL) or 6′-sialyllactose (6SL) and 
their potential to inhibit a diverse range of human and avian influenza virus strains. We show in a 
hemagglutination inhibition (HAI) assay that human IAV strains can be inhibited by (6SL)- and to a 
lesser extent also by (3SL)-conjugated PAMAM dendrimers. In contrast, avian strains could only be 
inhibited by (3SL)-conjugated dendrimers. Importantly, the differential sensitivities of human and 
avian IAV to the two types of sialyllactose-conjugated dendrimers could be confirmed in cell-based 
neutralization assays. Based on our findings, we suggest to further develop both, (3SL)- and (6SL)-
conjugated PAMAM dendrimers, as influenza virus inhibitors.
Influenza A virus (IAV) is the causative agent of influenza, a respiratory febrile disease in humans that is of 
medical and economic importance1. Vaccines are available to prevent influenza but unfortunately, the current 
vaccines come with severe limitations, such as reduced efficacy in the elderly or narrow specificity2. Hence, there 
is still a high demand for antivirals against influenza. For many years, two classes of antivirals were approved for 
clinical use: inhibitors of the viral ion channel M2 and inhibitors of the viral neuraminidase (NA). However, all 
strains of IAV currently circulating in humans are resistant to the M2 inhibitors, which leaves us with the NA 
inhibitors3,4. Unfortunately, the past has shown that widespread resistance against NA inhibitors can occur with 
minimal fitness costs5–7. Recently, a new drug for the treatment of influenza has been approved in Japan and the 
U.S.8 but rapid selection for drug resistant virus variants has been described for these endonuclease inhibitors9,10. 
Therefore, it is of high priority to develop novel antiviral agents. One promising strategy is to interfere with recep-
tor binding of IAV as such treatment could block the virus early and thereby efficiently11. IAV binds to cellular 
glycoproteins and glycolipids carrying terminal sialic acid (SA) residues via its envelope protein hemagglutinin 
(HA)12. Human isolates of IAV display a preference for SA in an α2,6-linkage to galactose, the penultimate sugar 
moiety, whereas avian IAV preferentially bind α2,3-linked SA13. Numerous SA-based inhibitors have been eval-
uated for their potential to inhibit IAV (reviewed in14). Early on, it became clear that unconjugated monomeric 
sialosides bind only weakly to HA and display low stability resulting in the need for non-physiological, poten-
tially toxic concentrations to efficiently inhibit virus infection15–17. Conjugation of SA to polymers has therefore 
been explored and proven more promising as higher affinity binding and improved stability can be achieved17–22. 
Dendritic polymers, such as polyamidoamine (PAMAM) dendrimers, can be conjugated to diverse ligands and 
represent one option to display SA in a multivalent manner23.
1Institute of Medical Virology, University of Zurich, 8057, Zurich, Switzerland. 2Glycom A/S, Kogle Alle 4, 2970, 
Hørsholm, Denmark. 3Institute of Physiology, University of Zurich, 8057, Zurich, Switzerland. 4These authors 
contributed equally: Julian David Maier and Janine Vetter. *email: stertz.silke@virology.uzh.ch
OPEN
2SCIENTIFIC REPORTS |          (2020) 10:768  | https://doi.org/10.1038/s41598-020-57608-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
The initial studies showed that hemagglutination inhibition of IAV could be achieved with SA-conjugated 
PAMAM dendrimers and that higher valency resulted in better inhibition17,22. Kwon and colleagues developed 
this approach further by coupling 6′-sialyllactose (6SL), a representative of the human-type IAV receptor, to 
PAMAM dendrimers rather than coupling SA directly to dendrimers21. This strategy revealed that not only 
valency, but also spacing between ligands affects the inhibitory potential. Interestingly, it was observed that 
different human strains of IAV displayed different sensitivities to inhibition by SA-PAMAMs22 but the num-
ber of strains tested was limited and the reasons behind differential sensitivity were unclear. Furthermore, only 
(6SL)-PAMAMs but not 3′-sialyllactose (3SL)-conjugates, which would represent the avian-type receptor speci-
ficity, have been tested so far.
Here, we synthesized PAMAM dendrimers branched with either 3SL or 6SL using a rapid and efficient method 
and assessed their potential to inhibit a diverse range of human and avian influenza virus strains. We show that 
hemagglutination of human IAV strains can be inhibited by (6SL)- but also (3SL)-conjugated PAMAM dendrim-
ers, whereas avian strains were only sensitive to (3SL)-PAMAMs. Importantly, these differential sensitivities of 
avian- and human-derived strains of IAV could be confirmed in cell culture-based neutralization assays. In sum-
mary, we conclude that both, (3SL)- and (6SL)-conjugated PAMAM dendrimers, should be further developed as 
IAV inhibitors.
Results
Sialyllactose-conjugated PAMAM dendrimers inhibit influenza virus hemagglutination. The 
trisaccharides 3SL and 6SL were first derivatized at their reducing end to cyclic carbamate24, which enabled the 
efficient conjugation of the sialyllactoses to primary amines in PAMAM backbones (Fig. 1). We then tested the 
tetrameric and octameric sialyllactose-conjugated dendrimers ((3SL)4-, (6SL)4-, (3SL)8- and (6SL)8-PAMAMs) 
for their ability to prevent influenza viruses from binding to their receptor in a hemagglutination inhibition (HAI) 
assay (Fig. 2a). Lactose-conjugated PAMAM lacking sialic acid residues served as negative control and did not 
show HAI activity with any virus at any of the concentrations tested. We first tested the compounds against two 
lab-adapted (A/WSN/1933 (WSN/33) and A/Puerto Rico/8/1934 (PR/8)) and two seasonal (A/Brisbane/59/2007 
Figure 1. Synthesis of the (6SL)8-PAMAM dendrimer. A commercial PAMAM dendrimer with 
ethylenediamine core depicted in pink and eight primary amino groups (generation 1 (G1)) was coupled to 
6′-sialyllactose (6SL)-cyclic carbamate derivatives (sialic acid is colored in red and lactose in blue with galactose 
in dark and glucose in light blue) in water at ambient temperature in 7 hours. The other three conjugates 
discussed in this article ((3SL)4-, (3SL)8- and (6SL)4-PAMAMs) were prepared analogously from tetravalent 
or octavalent PAMAMs with ethylenediamine core and corresponding (3SL)- or (6SL)-cyclic carbamates. 
r.t. = room temperature.
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(BR/59) and A/Netherlands/602/2009 (NL/09)) human-derived influenza strains of the H1N1 subtype. We 
observed that, except for PR/8, at least one of the four inhibitors works well in the low millimolar range with the 
octavalent compounds being more potent than the tetravalent. Interestingly, the lab-adapted H1N1 subtypes dis-
played better inhibition with (3SL)-conjugated PAMAMs, whereas the seasonal H1N1 strains were more potently 
inhibited by the (6SL)-linked PAMAMs although all strains are of human origin. Next, we tested human strains 
of the H3N2 subtype (A/Panama/2007/1999 (PA/99), A/Brisbane/10/2007 (BR/10) and (A/Hong Kong/1/1968 
(HK/68)) and detected a more potent antiviral activity for the octavalent dendrimers conjugated to the human-
type receptor. Strain PA/99 was particularly sensitive to HAI by (6SL)8-PAMAM with a minimal inhibitory con-
centration of <200 µM. When testing avian strains of influenza viruses (A/duck/England/1/1956 (EN/56), A/
Figure 2. Sialyllactose-conjugated dendrimers possess hemagglutination inhibition activity. (a) The minimal 
inhibitory concentration of PAMAM dendrimers conjugated to either 3′-sialyllactose (3SL) or 6′-sialyllactose 
(6SL) with either four or eight surface groups ((3SL)4-, (3SL)8-, (6SL)4- and (6SL)8-PAMAMs) against indicated 
viruses (asterisks indicate lab-adapted strains) was determined by hemagglutination inhibition (HAI) assay. If 
no inhibition was observed at concentrations of ≤5000 µM, a data point was placed on a dotted line indicating a 
minimal inhibitory concentration of >5000 µM. (b) The minimal inhibitory concentration of the two octavalent 
PAMAM dendrimers ((3SL)8- and (6SL)8-PAMAMs) against (A/WSN/1933 (WSN/33), A/Brisbane/59/2007 
(BR/59) and A/Brisbane/10/2007 (BR/10)) was determined in combination or individually by HAI assay. (c) The 
minimal inhibitory concentration of (3SL)4-, (3SL)8-, (6SL)4- and (6SL)8-PAMAMs was determined by HAI assay 
either with (w/) or without (w/o) pre-incubation of virus (A/Brisbane/59/2007) and PAMAM dendrimers. (a–c) 
For each condition, the results of three independent experiments are displayed on a scatter plot (one dot represents 
one experiment resulting in three dots per dendrimer per condition). Lactose-PAMAM lacking sialic acid residues 
was included as negative control and displayed no HAI activity at any of the concentrations tested.
4SCIENTIFIC REPORTS |          (2020) 10:768  | https://doi.org/10.1038/s41598-020-57608-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
duck/Ukraine/1/1963 (UK/63) and A/duck/Alberta/35/1976 (AL/76)), we could not detect any antiviral activity 
for the (6SL)-conjugated dendrimers. In contrast, the (3SL)-conjugated dendrimers, in particular the octavalent 
PAMAM, could inhibit all avian strains tested irrespective of the viral subtype. However, the minimal inhibitory 
concentration for all avian IAV strains was quite high (>2000 µM) compared to the human isolates. In addition to 
human and avian IAV strains, we also tested one swine IAV (A/sw/Zurich/04/2014 (Zu/14)) that showed a strong 
preference for (6SL)-conjugated PAMAM dendrimers in the HAI assay. Moreover, we also included a lab-adapted 
and a seasonal influenza B virus (IBV) strain (B/Yamagata/16/1988 and B/Phuket/3073/2013) and found that the 
lab-adapted IBV was inhibited by all four PAMAM variants with a slight preference for those conjugated to the 
avian-type receptor, whereas the seasonal IBV could only be inhibited by (6SL)8-PAMAMs.
Next, we chose three human-derived virus strains – one lab-adapted H1N1 (WSN/33), one seasonal H1N1 
(BR/59) and one seasonal H3N2 subtype (BR/10) – that were most sensitive in the HAI assay and assessed the 
antiviral activity of a combination of (3SL)8- and (6SL)8-PAMAMs (Fig. 2b). A mixture of the two octamers 
lead to an intermediate degree of inhibition of all virus strains. We also performed the HAI assay with BR/59 
and all four compounds with (w/) and without (w/o) pre-incubation of virus and inhibitor and found that the 
pre-incubation step slightly ameliorates the minimal inhibitory concentration (Fig. 2c).
Sialyllactose-conjugated PAMAM dendrimers minimally interfere with NA activity. In a next 
set of experiments, the inhibitors were analysed for their potential to interfere with NA activity of human IAV 
strains of the H1N1 subtype (WSN/33, BR/59 and NL/09), the H3N2 subtype (PA/99 and BR/10) and two avian 
IAV strains (UK/63 and AL/76). Besides all four sialyllactose-conjugated dendrimers ((3SL)4-, (3SL)8-, (6SL)4- 
and (6SL)8-PAMAMs), the Lactose-PAMAM without sialic acid residues on the surface was used as negative 
control and oseltamivir carboxylate (OC), a NA inhibitor, was used as positive control. As shown in Fig. 3a, NA 
activity of human BR/10 and avian AL/76 was minimally inhibited by (3SL)- but not (6SL)-conjugated PAMAM 
dendrimers. The IC50 values for all tested viruses and compounds are listed in Fig. 3b. The (3SL)-conjugated 
PAMAMs displayed low inhibitory activity for all tested viruses with IC50 values in the range of 50 to 170 µM for 
the (3SL)8-PAMAM. The (6SL)8-PAMAM only reached 50% inhibition for WSN/33 (IC50 220 µM) and PA/99 
(IC50 906 µM) but not for any other tested virus.
Sialyllactose-conjugated PAMAM dendrimers inhibit IAV infection in cell culture. Next, we 
examined the antiviral potential of the PAMAM dendrimers against two human (BR/10 and NL/09) and two 
avian (UK/63 and AL/76) IAV strains in a cell-based microneutralization (MN) assay (Fig. 4a). The results of the 
MN assay are in line with those of the HAI assay. We observed inhibition of strain BR/10 by both (6SL)-linked 
PAMAM dendrimers, whereas strain NL/09 was only inhibited by (6SL)8-PAMAM. However, the reductions 
in infection efficiency did not reach statistical significance. In contrast, avian IAV UK/63 was more sensitive to 
(3SL)-linked PAMAMs and inhibition was statistically significant for the highest concentration. Cells infected 
with avian AL/76 did not respond to any of the PAMAM dendrimers, which is also in line with the results of the 
HAI assay. The inhibitory effects of the PAMAM dendrimers on the different IAV strains are not due to cytotox-
icity of the inhibitors as treatment with 1 mM inhibitor for up to 48 hours did not reduce cell viability compared 
to the negative control, OC, and the positive control, cycloheximide (CHX) (Fig. 4b).
To strengthen the results of the MN assay, we performed an additional cell-based assay, a plaque reduction 
assay, with UK/63 and the (3SL)8-PAMAM as these conditions showed the strongest inhibition of viral infection 
in the MN assay (Fig. 4c). A complete abrogation of plaque formation was observed for the positive control OC. 
Strikingly, also the (3SL)8-PAMAM caused a reduction in plaque size when used at concentrations of ≥10 µM 
and completely prevented plaque formation at concentrations of ≥100 µM. These data show that (3SL)- and 
(6SL)-conjugated PAMAM dendrimers also show antiviral activity in cell-based assays.
Discussion
In this study, we synthesized (3SL)- and (6SL)-conjugated PAMAM dendrimers and tested them for activity 
against a broad range of influenza viruses. The HAI assay demonstrated that influenza viruses of human or 
swine origin were inhibited in binding to their receptors exposed on chicken erythrocytes by (6SL)-conjugated 
PAMAM dendrimers and to a lesser extent by (3SL)-conjugated PAMAM dendrimers, whereas avian IAV 
strains were only inhibited by dendrimers carrying the avian-type receptor. Nevertheless, strains WSN/33, PR/8 
and B/Yamagata/16/1988 form an exception as they are of human origin but displayed higher sensitivity to 
(3SL)-PAMAMs. This can be explained by the long history of egg passaging of these three lab-adapted viruses, 
which resulted in avian-type receptor specificity13,25. Furthermore, the data of the human H3N2 viruses also 
showed that sensitivity to the PAMAM-based inhibitors correlates with binding affinities of the viruses to their 
receptor: strain PA/99, shown to display much stronger glycan binding than strains HK/68 and BR/10, was most 
sensitive to sialyllactose-conjugated dendrimers26. The sialyllactose-conjugated PAMAM dendrimers could thus 
be used to determine receptor specificity and potentially also receptor affinity of influenza viruses.
As for some human-derived influenza viruses both the (3SL)- and the (6SL)-conjugated PAMAM dendrimers 
showed an inhibitory effect, we repeated the HAI assay for one of those viruses (BR/59) by mixing the (3SL)8- and 
the (6SL)8-PAMAMs but unfortunately, the combination did not result in a reduction of the minimal inhibitory 
concentration. Hence, a PAMAM dendrimer conjugated to both α2,3- and α2,6-linked SA might not increase the 
inhibitory effect but such broad-specificity inhibitors might be of advantage to inhibit strains of unknown tropism 
and those with dual receptor specificity, like the avian influenza A(H5N1)27 or A(H7N9)28 virus.
We also performed a NA activity assay to investigate whether the inhibitors are able to interfere with NA 
activity. Given that the dendrimers present sialic acid in its natural oligosaccharide context, we did not expect 
to observe strong inhibition and indeed, the sialyllactose-conjugated PAMAM dendrimers only slightly affected 
NA activity of the different IAV strains. Even though inhibition was minimal, it was interesting to see that the 
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(3SL)-conjugated polymers were more potent than the (6SL)-conjugated polymers against both, avian- and 
human-derived IAV strains. This is in line with published observations for N2 and N1 NA proteins of human 
viruses (H3N2 and H1N1) that prefer cleaving avian- over human-type receptors29,30 and indicates that the spec-
ificity of the NA protein does not need to fully match that of the corresponding HA protein.
To confirm the results from the in vitro assays in cell culture, we performed a MN assay and a plaque reduc-
tion assay to examine the potential of the PAMAM dendrimers to inhibit viral infection. In general, the HAI 
assay seems to be a good predictor for the cell-based MN assay although the effects in cell culture are rather 
small. Higher concentrations of the inhibitors might have increased the inhibitory effect of the PAMAMs but 
concentrations above 1 mM are not desirable for in vivo applications. Therefore, it would make sense to increase 
the number of surface groups rather than increasing the concentration as Kwon et al. could show that a PAMAM 
dendrimer of generation 4 (G4) with 64 surface groups and an optimized spacing between the (6SL) ligands 
showed the strongest binding to HA and the best inhibition of H1N1 infection21. The PAMAM dendrimers used 
in this study (generation 0 (G0) with 4 surface groups and generation 1 (G1) with 8 surface groups) are useful 
for proof-of-concept tests but those with a higher valency and the optimal interligand spacing should be further 
developed and envisaged for in vivo use.
In general, sialyllactose-conjugated dendrimers represent an attractive option for the development of novel 
antivirals for influenza as they mainly target HA, thereby enabling their combined application with drugs tar-
geting NA in order to maximize efficiency and reduce the emergence of antiviral drug resistance. However, the 
potential of PAMAM dendrimers of G0 and G1 is limited due to the high concentrations needed. This limitation 
can be overcome as shown by Kwon et al. who synthesized PAMAM dendrimers of generation 4 and 5 featuring 
up to 128 (6SL) ligands and observed potent antiviral activity in the low micromolar range21. Compared with 
the very slow incorporation of (6SL) ligands onto PAMAM dendrimers by reductive amination applied by Kwon 
Figure 3. Sialyllactose-conjugated dendrimers minimally interfere with neuraminidase function. (a) The 
neuraminidase (NA) activity of different IAV strains in the presence of PAMAM dendrimers conjugated 
to either 3′-sialyllactose (3SL) or 6′-sialyllactose (6SL) with either four or eight surface groups ((3SL)4-, 
(3SL)8-, (6SL)4- and (6SL)8-PAMAMs) was measured using the NA-Star Influenza Neuraminidase Inhibitor 
Resistance Detection Kit. Oseltamivir carboxylate served as positive control and Lactose-PAMAM lacking 
sialic acid residues was included as negative control. Values were normalized to untreated samples and fitted 
curves of A/Brisbane/10/2007 and A/duck/Alberta/35/1976 are shown. Error bars indicate the standard 
deviation (SD) of three independent experiments. (b) IC50 values in µM for all used IAV strains (A/WSN/1933 
(WSN/33), A/Brisbane/59/2007 (BR/59), A/Netherlands/602/2009 (NL/09), A/Panama/2007/1999 (PA/99), A/
Brisbane/10/2007 (BR/10), A/duck/Ukraine/1/1963 (UK/63) and A/duck/Alberta/35/1976 (AL/76)).
6SCIENTIFIC REPORTS |          (2020) 10:768  | https://doi.org/10.1038/s41598-020-57608-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
et al., the rapidity and efficiency of cyclic carbamate-mediated ligation employed here will enable the synthesis 
of large amounts of highly multivalent dendrimers. Overall, our results demonstrate host-specific inhibition of 
influenza virus infection with (3SL)- and (6SL)-linked PAMAM dendrimers further supporting the strategy to 
use multivalent inhibitors as treatment and prophylaxis for influenza.
Figure 4. Sialyllactose-conjugated dendrimers inhibit influenza A virus in cell-based assays. (a) PAMAM 
dendrimers conjugated to lactose with no sialic acid residues (Lactose-PAMAM) or to 3′-sialyllactose (3SL) or 
6′-sialyllactose (6SL) with either four or eight surface groups ((3SL)4-, (3SL)8-, (6SL)4- and (6SL)8-PAMAMs) 
were pre-incubated with virus (A/Brisbane/10/2007 (BR/10), A/Netherlands/602/2009 (NL/09), A/duck/
Ukraine/1/1963 (UK/63) or A/duck/Alberta/35/1976 (AL/76)) for 1 hour at 4 °C. MDCK cells were infected with 
the compound-virus mix at low multiplicity of infection (MOI) for 1 hour at 37 °C. After removing the inoculum, 
cells were incubated for up to 24 hours at 37 °C in infection medium containing PAMAM dendrimers. Cells 
were fixed and stained for the viral nucleoprotein (NP) and DAPI to counterstain the nucleus. The NP signal was 
quantified and values were normalized to non-treated but infected samples (non-inhibitor control (non-inh. 
ctrl.)). Error bars indicate the standard deviation (SD) of three independent experiments, each being performed 
in triplicates. Significance was determined by one-way ANOVA (*P <0.05). (b) MDCK cells were treated with 
1 mM of the different PAMAM dendrimers (Lactose-, (3SL)4-, (3SL)8-, (6SL)4- and (6SL)8-PAMAMs), the 
negative control oseltamivir carboxylate (OC) or the positive control cycloheximide (CHX), which is known to 
be cytotoxic, for either 24 or 48 hours. After treatment, cell viability was assessed using the CellTiter-Glo assay. 
Error bars indicate the standard deviation (SD) of three independent experiments. (c) Confluent MDCK cells 
were infected with 30 plaque-forming units of A/duck/Ukraine/1/1963 for 1 hour at 37 °C before the agar overlay 
containing the indicated concentrations (conc.) of the positive control OC, the (3SL)8-PAMAM or no inhibitor 
(negative control) was added and incubated at 37 °C until plaques were visible. Cells were then fixed and stained 
with crystal violet and plaques were counted (plaque quantity (qty.)) and measured (plaque diameter (dia.) in 
mm). Mean values with standard deviation (SD) of three independent experiments are listed.
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Materials and Methods
Inhibitor synthesis. The disaccharide lactose and the trisaccharides 3SL and 6SL were first derivatized 
at their reducing end to cyclic carbamate24, which enabled the efficient conjugation of the saccharides to pri-
mary amines in PAMAM backbones. Cyclic carbamate-derivatized lactose, 3SL or 6SL (in excess of 2–3 molar 
equivalents per amino group of PAMAM) were reacted with commercial PAMAM dendrimers (Sigma-Aldrich; 
ethylenediamine core, generation 0 or 1) within several hours at ambient temperature in water. The obtained 
fully derivatized dendrimers (Lactose-PAMAM, (3SL)4-PAMAM, (6SL)4-PAMAM, (3SL)8-PAMAM and (6SL)8-
PAMAM) were initially purified by ion-exchange chromatography (Lactose-PAMAM on Dowex-50WX4-H+ and 
(6SL)4-PAMAM on Dowex-1 × 4-HCO3
−) followed by freeze-drying. However, direct precipitation with meth-
anol from the reaction mixture proved to be the most efficient and simple method of product isolation. Thus, all 
glycodendrimers were efficiently precipitated by dropwise addition of the reaction mixture to the stirring volume 
of methanol. The structural integrity of conjugates was confirmed by high-resolution electrospray-ionization 
mass spectrometry and nuclear magnetic resonance (NMR). Lyophilized PAMAMs were dissolved in Dulbecco’s 
Modified Eagle Medium (DMEM), filtered through a 0.22 µm filter and stored at −20 °C until use.
Viruses and cell lines. All virus strains except NL/09 and B/Phuket/3073/2013 were grown in 10-day-old 
embryonated chicken eggs. The study is exempt from the need for ethical approval under Swiss regulations 
(Tierschutzverordnung 455.1), as virus growth in the chicken eggs was completed before the end of the sec-
ond trimester. To confirm that egg-passaging of our virus stocks did not cause changes in receptor specific-
ity, egg-grown virus stocks of BR/10 and BR/59 were selected as representatives and sequenced. Comparison 
to the respective reference sequence derived from tissue culture grown virus stocks revealed no changes in HA 
that could affect receptor specificity. Strains B/Phuket/3073/2013 and NL/09 were grown in MDCK cells (The 
European Collection of Authenticated Cell Cultures (ECACC)). Virus stocks were titered in triplicates by plaque 
assay on MDCK cells (see below). MDCK cells were grown in DMEM supplemented with 10% fetal calf serum 
(FCS), 100 U/ml penicillin and 100 µg/ml streptomycin.
Hemagglutination inhibition (HAI) assay. HAI assays were performed as described previously31,32. In 
brief, two-fold serial dilutions of the inhibitors were pre-incubated in a 96-well plate with 8 HA units of virus per 
well for 30 min at 4 °C. Chicken erythrocytes (Bell AG), that contain α2,3-linked and α2,6-linked SA receptors 
on their surface, were added at a final concentration of 0.5%, and the plate was incubated at room temperature 
(RT) for 45 min. HAI titers were determined as the highest dilution that displayed inhibition of hemagglutinating 
activity referred to as minimal inhibitory concentration.
Neuraminidase (NA) activity assay. NA activity was measured using the NA-Star Influenza 
Neuraminidase Inhibitor Resistance Detection Kit (Applied BiosystemsTM) according to the manufacturer’s 
instructions. The values were normalized to the untreated control, which is set to a 100%, and IC50 values were 
calculated by nonlinear regression analysis (GraphPad Prism 7).
Virus titration by plaque assay. MDCK cells were seeded into 12-well plates. Upon complete confluency, 
cells were infected with a 10-fold dilution series of virus and incubated for 1 hour at 37 °C with regular shaking of 
the plates. The agar overlay (25 mL 2x MEM with 9 ml water, 0.5 ml DEAE dextran (1%), 0.75 ml sodium bicar-
bonate (7.5%), 17.5 ml OxoidTM purified agar (2%) and 1 µg/ml Tosylamide-2-phenylethyl-chloromethyle-ketone 
(TPCK)-treated trypsin) was added to each well and cells were incubated at 37 °C until plaques were visible. Cells 
were fixed with 3.7% paraformaldehyde (PFA) and stained with a crystal violet solution (0.05% crystal violet and 
16% methanol in ddH2O).
Plaque reduction assay. Confluent MDCK cells in a 12-well plate were infected with 30 plaque-forming 
units (PFU) of the indicated virus for 1 hour at 37 °C. After infection, the virus inoculum was removed and 
replaced by the agar overlay containing the sialyllactose-conjugated dendrimers at different concentrations (1 µM 
to 1 mM) or OC (1 µM) as positive control. Following incubation at 37 °C until plaques were visible, cells were 
fixed with 3.7% PFA and stained with crystal violet solution. Finally, plaques were counted and measured.
Microneutralization (MN) assay. MDCK cells were seeded in a 96-well plate (1.5 × 104 cells/well). The 
next day, PAMAM dendrimers (5, 50 and 500 µM) were pre-incubated with virus at low multiplicity of infection 
(MOI) for 1 hour at 4 °C before cells were infected with the compound-virus mix for 1 hour at 37 °C. Following 
infection, the inoculum was removed and replaced by infection medium (DMEM supplemented with 0.1% FCS, 
3% BSA, 20 mM Hepes, 100 U/ml penicillin, 100 µg/ml streptomycin and 1 µg/ml (TPCK)-treated trypsin) con-
taining PAMAM dendrimers at the specific concentrations. After incubation of up to 24 hours at 37 °C depending 
on the virus kinetics, cells were fixed with 3.7% PFA for 10 min at RT, permeabilized with 0.5% Triton X-100 for 
5 min at RT and stained with 4′,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei and a mouse mono-
clonal antibody against the viral nucleoprotein (HB-65, American Type Culture Collection)33. Following incu-
bation with the secondary antibody (goat anti-mouse Alexa Fluor 488; Invitrogen), the NP signal was measured 
using a microplate reader (Perkin Elmer). The values were normalized to the non-inhibitor control (cells + virus 
without inhibitor = 100%) and analysed by one-way ANOVA (Graph Pad Prism 7) for comparison of multiple 
conditions. The P values for significance are stated in the figure legend.
Data availability
The authors confirm that the data supporting the findings of this study are available within the paper.
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